Free Trial
LON:ARR

Aurora Investment Trust 3/31/2026 Earnings Report

Aurora Investment Trust logo
GBX 235 -4.00 (-1.67%)
As of 11:57 AM Eastern

Aurora Investment Trust EPS Results

Actual EPS
GBX 4.59
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aurora Investment Trust Revenue Results

Actual Revenue
$6.50 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aurora Investment Trust Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Aurora Investment Trust Earnings Headlines

Aurora UK Alpha PLC Announces Share Buyback
Aurora UK Alpha plc (ARR.L)
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targeting measles - a disease with no approved antiviral treatment and rising global case counts. Beyond measles, NV-387 is designed as a broad-spectrum platform targeting RSV, influenza, coronaviruses, and Mpox, giving NNVC exposure to multiple large markets as Phase II trials advance. The designation unlocks faster development timelines, financial incentives, and potential market exclusivity.tc pixel
See More Aurora Investment Trust Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aurora Investment Trust? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurora Investment Trust and other key companies, straight to your email.

About Aurora Investment Trust

Aurora UK Alpha plc is a UK listed Investment Trust which strives to provide shareholders with long term returns through capital and income growth by investing predominantly in a portfolio of UK listed companies.

View Aurora Investment Trust Profile